Literature DB >> 28645607

The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer.

Fabio Ciccarone1, Rolando Vegliante1, Luca Di Leo1, Maria Rosa Ciriolo2.   

Abstract

Cancer cells exploit metabolic rearrangements for sustaining their high proliferation rate and energy demand. The TCA cycle is a central metabolic hub necessary for ATP production and for providing precursors used in many biosynthetic pathways. Thus, dysregulation of the TCA cycle flux is frequently observed in cancer. The identification of mutations in several enzymes of the TCA cycle in human tumours demonstrated a direct connection between this metabolic pathway and cancer occurrence. Moreover, changes in the expression/activity of these enzymes were also shown to promote metabolic adaptation of cancer cells. In this review, the main genetic and non-genetic alterations of TCA cycle in cancer will be described. Particular attention will be given to extrametabolic roles of TCA cycle enzymes and metabolites underlying the regulation of nuclear and mitochondrial DNA transactions.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epigenetics; Oncometabolism; TCA cycle; mtDNA

Mesh:

Substances:

Year:  2017        PMID: 28645607     DOI: 10.1016/j.semcancer.2017.06.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  13 in total

1.  Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock.

Authors:  Zhen Dong; Guoxin Zhang; Meng Qu; Ryan C Gimple; Qiulian Wu; Zhixin Qiu; Briana C Prager; Xiuxing Wang; Leo J Y Kim; Andrew R Morton; Deobrat Dixit; Wenchao Zhou; Haidong Huang; Bin Li; Zhe Zhu; Shideng Bao; Stephen C Mack; Lukas Chavez; Steve A Kay; Jeremy N Rich
Journal:  Cancer Discov       Date:  2019-08-27       Impact factor: 39.397

2.  Atg7 inhibits Warburg effect by suppressing PKM2 phosphorylation resulting reduced epithelial-mesenchymal transition.

Authors:  Yanling Feng; Jingwei Liu; Wendong Guo; Yi Guan; Hongde Xu; Qiqiang Guo; Xiaoyu Song; Fei Yi; Ting Liu; Wenyu Zhang; Xiang Dong; Longyue L Cao; Brian P O'Rourke; Liu Cao
Journal:  Int J Biol Sci       Date:  2018-05-12       Impact factor: 6.580

Review 3.  The role of YAP/TAZ activity in cancer metabolic reprogramming.

Authors:  Xiaodong Zhang; Haiying Zhao; Yan Li; Di Xia; Liang Yang; Yingbo Ma; Hangyu Li
Journal:  Mol Cancer       Date:  2018-09-03       Impact factor: 27.401

4.  Aconitase 2 inhibits the proliferation of MCF-7 cells promoting mitochondrial oxidative metabolism and ROS/FoxO1-mediated autophagic response.

Authors:  Fabio Ciccarone; Luca Di Leo; Giacomo Lazzarino; Giuseppe Maulucci; Flavio Di Giacinto; Barbara Tavazzi; Maria Rosa Ciriolo
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

Review 5.  Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities.

Authors:  Carina Neitzel; Philipp Demuth; Simon Wittmann; Jörg Fahrer
Journal:  Cancers (Basel)       Date:  2020-06-29       Impact factor: 6.639

6.  A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma.

Authors:  Chaocai Zhang; Minjie Wang; Fenghu Ji; Yizhong Peng; Bo Wang; Jiannong Zhao; Jiandong Wu; Hongyang Zhao
Journal:  Biomed Res Int       Date:  2021-01-22       Impact factor: 3.411

Review 7.  Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors.

Authors:  Xianhu Zeng; Zhipeng Li; Chunrong Zhu; Lisa Xu; Yong Sun; Shangcong Han
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

8.  A Comparative Analysis of Metabolic Profiles of Embryonic Skeletal Muscle from Lantang and Landrace Pigs.

Authors:  Shufang Cai; Tianqi Duo; Xiaoyu Wang; Xian Tong; Chenglong Luo; Yaosheng Chen; Jianhao Li; Delin Mo
Journal:  Animals (Basel)       Date:  2022-02-10       Impact factor: 2.752

9.  Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.

Authors:  Luca Di Leo; Rolando Vegliante; Fabio Ciccarone; Illari Salvatori; Manuel Scimeca; Elena Bonanno; Andrea Sagnotta; Gian Luca Grazi; Katia Aquilano; Maria Rosa Ciriolo
Journal:  Oncogene       Date:  2018-10-26       Impact factor: 9.867

10.  PolG Inhibits Gastric Cancer Glycolysis and Viability by Suppressing PKM2 Phosphorylation.

Authors:  Mengzhu Lv; Simeng Zhang; Yuqing Dong; Liu Cao; Shu Guo
Journal:  Cancer Manag Res       Date:  2021-02-16       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.